The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
Acquisition expands high-value medical platform
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Aims to become India’s leading cancer testing company
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Subscribe To Our Newsletter & Stay Updated
